Toxoplasmic encephalitis in AIDS-patients before and after the introduction of highly active antiretroviral therapy (HAART)

  • T. R. Kiderlen
  • O. Liesenfeld
  • D. Schürmann
  • T. Schneider
Article

Abstract

Toxoplasmic encephalitis (TE) continues to be a severe health problem despite the introduction of highly active antiretroviral therapy (HAART). To identify predictors for development of TE we compared demographic, clinical and diagnostic variables in AIDS patients with TE before (n = 102) or after the introduction (n = 70) of HAART at the Charité University Medicine in Berlin, Germany. Interestingly, patient characteristics did not differ significantly in the pre- and post-HAART groups. Sixty-eight percent of patients had CD4-cell counts of <50/μl. Outcome after treatment with pyrimethamin plus sulfonamides or clindamycin (47% each) did not differ; adverse reactions were more frequent in patients receiving sulfonamides than in those receiving clindamycin (25% vs. 10.5%; p = 0.02). Interestingly, patients in the post HAART group had not received (82.9%) or had not taken HAART adequately (17.1%). Concurrent diagnosis of TE and HIV was significantly more often in the post- compared to the pre-HAART group (49 vs. 26%, respectively; p > 0.001). Thus, despite the introduction of HAART, awareness of opportunistic infections in HIV patients is warranted. High rates of unawareness of HIV infection should make public health efforts focus on early identification of HIV infection and initiation of and compliance with HAART.

Notes

Conflict of interest

None.

References

  1. 1.
    Montoya JG, Liesenfeld O (2004) Toxoplasmosis. Lancet 363(9425):1965–1976PubMedCrossRefGoogle Scholar
  2. 2.
    Luft BJ, Castro KG (1991) An overview of the problem of toxoplasmosis and pneumocystosis in AIDS in the USA: implication for future therapeutic trials. Eur J Clin Microbiol Infect Dis 10(3):178–181PubMedCrossRefGoogle Scholar
  3. 3.
    Mathews WC, Fullerton SC (1994) Use of a clinical laboratory database to estimate Toxoplasma seroprevalence among human immunodeficiency virus-infected patients. Overcoming bias in secondary analysis of clinical records. Arch Pathol Lab Med 118(8):807–810PubMedGoogle Scholar
  4. 4.
    Clumeck N (1991) Some aspects of the epidemiology of toxoplasmosis and pneumocystosis in AIDS in Europe. Eur J Clin Microbiol Infect Dis 10(3):177–178PubMedCrossRefGoogle Scholar
  5. 5.
    Zumla A, Savva D, Wheeler RB, Hira SK, Luo NP, Kaleebu P, Sempala SK, Johnson JD, Holliman R (1991) Toxoplasma serology in Zambian and Ugandan patients infected with the human immunodeficiency virus. Trans R Soc Trop Med Hyg 85(2):227–229PubMedCrossRefGoogle Scholar
  6. 6.
    Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Selnes OA, Miller EN, Becker JT, Cohen B, McArthur JC (2001) HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990–1998. Neurology 56(2):257–260PubMedGoogle Scholar
  7. 7.
    Abgrall S, Rabaud C, Costagliola D (2001) Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era. Clin Infect Dis 33(10):1747–1755PubMedCrossRefGoogle Scholar
  8. 8.
    San-Andres FJ, Rubio R, Castilla J, Pulido F, Palao G, de Pedro I, Costa JR, del Palacio A (2003) Incidence of acquired immunodeficiency syndrome-associated opportunistic diseases and the effect of treatment on a cohort of 1,115 patients infected with human immunodeficiency virus, 1989–1997. Clin Infect Dis 36(9):1177–1185PubMedCrossRefGoogle Scholar
  9. 9.
    Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H (2009) Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 58(RR-4):1–207; quiz CE201-204Google Scholar
  10. 10.
    Antinori A, Larussa D, Cingolani A, Lorenzini P, Bossolasco S, Finazzi MG, Bongiovanni M, Guaraldi G, Grisetti S, Vigo B, Gigli B, Mariano A, Dalle Nogare ER, De Marco M, Moretti F, Corsi P, Abrescia N, Rellecati P, Castagna A, Mussini C, Ammassari A, Cinque P, d'Arminio Monforte A (2004) Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy. Clin Infect Dis 39(11):1681–1691PubMedCrossRefGoogle Scholar
  11. 11.
    Robert Koch-Institut B (2009) SurvStat. Robert Koch-Institut, GermanyGoogle Scholar
  12. 12.
    Centers for Disease Control and Prevention (CDC) (2010) Prevalence and awareness of HIV infection among men who have sex with men—21 cities, United States, 2008. MMWR Morb Mortal Wkly Rep 59(37):1201–1207Google Scholar
  13. 13.
    Menendez-Arias L (2010) Molecular basis of human immunodeficiency virus drug resistance: an update. Antiviral Res 85(1):210–231PubMedCrossRefGoogle Scholar
  14. 14.
    Paredes R, Clotet B (2010) Clinical management of HIV-1 resistance. Antiviral Res 85(1):245–265PubMedCrossRefGoogle Scholar
  15. 15.
    Spire B, Duran S, Souville M, Leport C, Raffi F, Moatti JP (2002) Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc Sci Med 54(10):1481–1496PubMedCrossRefGoogle Scholar
  16. 16.
    Carrieri MP, Leport C, Protopopescu C, Cassuto JP, Bouvet E, Peyramond D, Raffi F, Moatti JP, Chene G, Spire B (2006) Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. J Acquir Immune Defic Syndr 41(4):477–485PubMedCrossRefGoogle Scholar
  17. 17.
    Kerr T, Palepu A, Barness G, Walsh J, Hogg R, Montaner J, Tyndall M, Wood E (2004) Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver. Antivir Ther 9(3):407–414PubMedGoogle Scholar
  18. 18.
    Protopopescu C, Raffi F, Roux P, Reynes J, Dellamonica P, Spire B, Leport C, Carrieri MP (2009) Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data. J Antimicrob Chemother 64(3):599–606PubMedCrossRefGoogle Scholar
  19. 19.
    Vidal JE, Hernandez AV, de Oliveira AC, Dauar RF, Barbosa SP Jr, Focaccia R (2005) Cerebral toxoplasmosis in HIV-positive patients in Brazil: clinical features and predictors of treatment response in the HAART era. AIDS Patient Care STDs 19(10):626–634PubMedCrossRefGoogle Scholar
  20. 20.
    Phillips A, Pezzotti P (2004) Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS 18(1):51–58PubMedCrossRefGoogle Scholar
  21. 21.
    Garly ML, Petersen E, Pedersen C, Lundgren JD, Gerstoft J (1997) Toxoplasmosis in Danish AIDS patients. Scand J Infect Dis 29(6):597–600PubMedCrossRefGoogle Scholar
  22. 22.
    Ives NJ, Gazzard BG, Easterbrook PJ (2001) The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART) in a London clinic. J Infect 42(2):134–139PubMedCrossRefGoogle Scholar
  23. 23.
    Ammassari A, Cingolani A, Pezzotti P, De Luca DA, Murri R, Giancola ML, Larocca LM, Antinori A (2000) AIDS-related focal brain lesions in the era of highly active antiretroviral therapy. Neurology 55(8):1194–1200PubMedGoogle Scholar
  24. 24.
    Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360(9327):119–129PubMedCrossRefGoogle Scholar
  25. 25.
    Girardi E, Sabin CA, Monforte AD (2007) Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing. J Acquir Immune Defic Syndr 46(Suppl 1):S3–S8PubMedCrossRefGoogle Scholar
  26. 26.
    Luft BJ, Hafner R, Korzun AH, Leport C, Antoniskis D, Bosler EM, Bourland DD 3rd, Uttamchandani R, Fuhrer J, Jacobson J et al (1993) Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team. N Engl J Med 329(14):995–1000PubMedCrossRefGoogle Scholar
  27. 27.
    Levy RM, Bredesen DE, Rosenblum ML (1985) Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature. J Neurosurg 62(4):475–495PubMedCrossRefGoogle Scholar
  28. 28.
    Firsching RW, Dieter, Reissberg S, Döhring W, Peters B (2003) Prognostische Bedeutung der MRT bei Bewusstlosigkeit nach Schädel-Hirn-Verletzung. Deutsches Ärzteblatt 100:A-1868Google Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • T. R. Kiderlen
    • 1
  • O. Liesenfeld
    • 1
  • D. Schürmann
    • 2
  • T. Schneider
    • 3
  1. 1.Institute for Microbiology and Hygiene, Campus Benjamin FranklinCharité Medical School BerlinBerlinGermany
  2. 2.Department of Internal Medicine, Infectious Diseases & Pulmonary Medicine, Campus Virchow KlinikumCharité Medical School BerlinBerlinGermany
  3. 3.Department of Medicine I, Gastroenterology, Infectious Diseases & Rheumatology, Campus Benjamin FranklinCharité Medical School BerlinBerlinGermany

Personalised recommendations